NCT05025358View on ClinicalTrials.gov

A Study of LP-118 in Patients With Advanced Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

July 9, 2025

Study Completion Date

December 30, 2025

Conditions
Solid TumorLymphoma, Non-Hodgkin
Interventions
DRUG

LP-118 tablet

Subjects will administered orally with LP-118 tablet at the designated dose once daily, using approximately 240 mL of water during a meal or within 30 minutes after a meal, 28 days per cycle. The treatment will continue until progressive disease, unacceptable toxicity, etc.

Trial Locations (4)

310006

First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

430022

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

510080

Guangdong Provincial People's Hospital, Guangzhou

510632

The First Affiliated Hospital of Jinan University, Guangzhou

All Listed Sponsors
lead

Guangzhou Lupeng Pharmaceutical Company LTD.

INDUSTRY